drugset / Trial / NCT07511647
A Phase 3 Clinical Study of QL2106 Injection
RandomizedParallel-groupQuadruple-blindTreatment
Summary
It is a multicenter randomized, double-blinded, parallel, positive-controlled, Phase 3 comparative study to evaluate the efficacy and safety of QL2106 injection to Tremfya® in Patients with Moderate to Severe Plaque Psoriasis. A total of 318 subjects are planned to be included and randomized at a ratio of 1:1 to receive QL2106 injection orTremfya®
Timeline
- Start
- 2026-06-15
- Primary completion
- 2027-12-30
- Completion
- 2028-02-28
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Guselkumab | Monoclonal antibody | 100 mg | Subcutaneous |
| Subject | QL2106 | Unknown | 100 mg | Subcutaneous |